OpenAI Startup Fund and Founders Fund Back Coherence Neuro's $45 Million Round for Tumor-Monitoring Brain Implants
Summary
Coherence Neuro has raised $45 million in a round co-led by the OpenAI Startup Fund and Founders Fund, with participation from Lux Capital, 8VC and others. The company, co-founded in 2022 by Ben Woodington and Elise Jenkins, is building a button-sized implant called SOMA that records electrical signals from tumors and can deliver its own stimulation to slow their growth, starting with glioblastoma. Human testing so far is limited to safety tests in consenting patients, where implants are removed after about 30 minutes during other surgeries. The company says its next step is a first chronic human trial in glioblastoma and that it is seeking FDA breakthrough device designation. Clinical benefit is unproven.
Why it matters
It brings AI-industry and tech-investor capital into brain implants aimed at cancer, a new use for neural recording and stimulation. The human work is brief intraoperative testing, so the round is not evidence that a cancer-detecting implant is near clinical use.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items โ updated daily.
Start free trial